What is it about?

We address genetic and imaging markers, and other developments in predicting risk. Further improvements in risk stratification are expected with the addition of genetic risk scores. In addition to single nucleotide polymorphisms (SNPs), recent advances in epigenetics offer DNA methylation profiles, histone chemical modifications, and micro-RNAs as other promising indicators of atherosclerosis. Imaging biomarkers are better studied and already have a higher degree of clinical applicability in cardiovascular (CV) event prediction and detection of preclinical atherosclerosis. With new methodologies, such as proteomics and metabolomics, discoveries of new clinically applicable biomarkers are expected.

Featured Image

Read the Original

This page is a summary of: Markers of Atherosclerosis: Part 2 – Genetic and Imaging Markers, Heart Lung and Circulation, May 2019, Elsevier,
DOI: 10.1016/j.hlc.2018.09.006.
You can read the full text:

Read

Contributors

The following have contributed to this page